Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Placebo-controlled, Double-Blind Phase 2 Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity, With an Open-Label Extension

Next Previous
Trial Profile

A Randomized, Placebo-controlled, Double-Blind Phase 2 Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity, With an Open-Label Extension

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bivamelagon (Primary)
  • Indications Obesity
  • Focus Therapeutic Use
  • Acronyms SIGNAL
  • Sponsors LG Chem; Rhythm

Most Recent Events

  • 12 Jul 2025 According to a Rhythm Pharmaceuticals media release, data from this trial was presented at the Endocrine Societys Annual Meeting (ENDO 2025) taking place July 12 to 15 in San Francisco, CA.
  • 12 Jul 2025 Results presented in the Rhythm media release.
  • 09 Jul 2025 According to a Rhythm Pharmaceuticals media release, the Company plans to request an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) and to seek scientific advice from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top